GlaxoSmithKlineE Past Earnings Performance
Past criteria checks 1/6
GlaxoSmithKlineE's earnings have been declining at an average annual rate of -20.9%, while the Pharmaceuticals industry saw earnings growing at 6% annually. Revenues have been growing at an average rate of 5.2% per year. GlaxoSmithKlineE's return on equity is 3.1%, and it has net margins of 2.7%.
Key information
-20.9%
Earnings growth rate
-20.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 9.8% |
| Revenue growth rate | 5.2% |
| Return on equity | 3.1% |
| Net Margin | 2.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How GlaxoSmithKlineE makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,240 | 60 | 348 | 0 |
| 30 Sep 23 | 2,131 | -139 | 285 | 0 |
| 30 Jun 23 | 2,107 | -117 | 346 | 0 |
| 31 Mar 23 | 1,914 | -120 | 360 | 0 |
| 31 Dec 22 | 1,823 | -114 | 338 | 0 |
| 30 Sep 22 | 2,099 | 193 | 378 | 0 |
| 30 Jun 22 | 1,959 | 193 | 388 | 0 |
| 31 Mar 22 | 2,042 | 209 | 433 | 0 |
| 31 Dec 21 | 1,812 | 155 | 440 | 0 |
| 30 Sep 21 | 1,549 | -40 | 400 | 0 |
| 30 Jun 21 | 1,627 | -104 | 393 | 0 |
| 31 Mar 21 | 1,699 | -42 | 395 | 0 |
| 31 Dec 20 | 1,993 | 28 | 495 | 0 |
| 30 Sep 20 | 1,930 | 177 | 499 | 0 |
| 30 Jun 20 | 1,878 | 230 | 503 | 0 |
| 31 Mar 20 | 1,764 | 175 | 508 | 0 |
| 31 Dec 19 | 1,704 | 143 | 474 | 0 |
| 30 Sep 19 | 1,690 | -13 | 467 | 0 |
| 30 Jun 19 | 1,645 | 19 | 473 | 0 |
| 31 Mar 19 | 1,630 | 32 | 455 | 0 |
| 31 Dec 18 | 1,623 | 50 | 442 | 0 |
| 30 Sep 18 | 1,563 | -3 | 439 | 0 |
| 30 Jun 18 | 1,556 | 59 | 410 | 0 |
| 31 Mar 18 | 1,508 | 106 | 408 | 0 |
| 31 Dec 17 | 1,453 | 102 | 372 | 0 |
| 30 Sep 17 | 1,350 | 162 | 316 | 0 |
| 30 Jun 17 | 1,238 | 135 | 304 | 0 |
| 31 Mar 17 | 1,207 | 87 | 267 | 0 |
| 31 Dec 16 | 1,166 | -4 | 246 | 0 |
| 30 Sep 16 | 1,116 | 270 | 209 | 0 |
| 30 Jun 16 | 1,094 | 138 | 178 | 0 |
| 31 Mar 16 | 1,080 | 73 | 186 | 0 |
| 31 Dec 15 | 1,010 | 69 | 183 | 0 |
| 30 Sep 15 | 1,031 | -96 | 170 | 0 |
| 30 Jun 15 | 1,054 | -44 | 176 | 0 |
| 31 Mar 15 | 1,031 | -19 | 165 | 0 |
| 31 Dec 14 | 1,062 | 64 | 171 | 0 |
| 30 Sep 14 | 1,077 | 66 | 197 | 0 |
| 30 Jun 14 | 1,061 | 73 | 192 | 0 |
| 31 Mar 14 | 1,051 | 74 | 198 | 0 |
| 31 Dec 13 | 1,041 | 77 | 192 | 0 |
| 30 Sep 13 | 982 | 83 | 187 | 0 |
| 30 Jun 13 | 959 | 51 | 187 | 0 |
Quality Earnings: BIOC has a large one-off loss of EGP145.4M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: BIOC became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOC's earnings have declined by 20.9% per year over the past 5 years.
Accelerating Growth: BIOC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BIOC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (27.9%).
Return on Equity
High ROE: BIOC's Return on Equity (3.1%) is considered low.